Literature DB >> 21797658

Corticosteroid use in neurocysticercosis.

Theodore E Nash1, Siddhartha Mahanty, Hector H Garcia.   

Abstract

The cystic larvae of Taenia solium commonly infect the human nervous system, resulting in neurocysticercosis, a major contributor to seizure disorders in most of the world. Inflammation around the parasites is a hallmark of neurocysticercosis pathophysiology. Although mechanisms regulating this inflammation are poorly understood, anti-inflammatory drugs, particularly corticosteroids, have been long used alone or with anthelmintics to manage disease and limit neurological complications and perhaps damage to neural tissues. Only scarce controlled data exist to determine when and what type of corticosteroids and the treatment regime to use. This article revisits the mechanisms of action, rationale, evidence of benefit, safety and problems of corticosteroids in the context of neurocysticercosis, as well as alternative anti-inflammatory strategies to limit the damage caused by inflammation in the CNS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21797658      PMCID: PMC3721198          DOI: 10.1586/ern.11.86

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  60 in total

1.  Differential effects of corticosteroids during different stages of dendritic cell maturation.

Authors:  M K Matyszak; S Citterio; M Rescigno; P Ricciardi-Castagnoli
Journal:  Eur J Immunol       Date:  2000-04       Impact factor: 5.532

2.  New developments in the management of neurocysticercosis.

Authors:  A Clinton White
Journal:  J Infect Dis       Date:  2009-05-01       Impact factor: 5.226

3.  Short report: A calcified Taenia solium granuloma associated with recurrent perilesional edema causing refractory seizures: histopathological features.

Authors:  Winnie W Ooi; Subhashie Wijemanne; Christine B Thomas; Martha Quezado; Charles R Brown; Theodore E Nash
Journal:  Am J Trop Med Hyg       Date:  2011-09       Impact factor: 2.345

Review 4.  The role of the glucocorticoid receptor in inflammation and immunity.

Authors:  Ulrike Baschant; Jan Tuckermann
Journal:  J Steroid Biochem Mol Biol       Date:  2010-03-24       Impact factor: 4.292

5.  Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor.

Authors:  H M Reichardt; J P Tuckermann; M Göttlicher; M Vujic; F Weih; P Angel; P Herrlich; G Schütz
Journal:  EMBO J       Date:  2001-12-17       Impact factor: 11.598

6.  Calcified cysticerci provoke perilesional edema and seizures.

Authors:  T E Nash; J Pretell; H H Garcia
Journal:  Clin Infect Dis       Date:  2001-10-05       Impact factor: 9.079

Review 7.  Clinical heterogeneity of human neurocysticercosis results from complex interactions among parasite, host and environmental factors.

Authors:  Agnès Fleury; Alfonso Escobar; Gladis Fragoso; Edda Sciutto; Carlos Larralde
Journal:  Trans R Soc Trop Med Hyg       Date:  2010-01-29       Impact factor: 2.184

8.  Inhibition of glucocorticoid-mediated, caspase-independent dendritic cell death by CD40 activation.

Authors:  K D Kim; Y K Choe; I S Choe; J S Lim
Journal:  J Leukoc Biol       Date:  2001-03       Impact factor: 4.962

Review 9.  Neurocysticercosis in children.

Authors:  Pratibha Singhi; Sunit Singhi
Journal:  Indian J Pediatr       Date:  2009-05-24       Impact factor: 1.967

10.  Cysticercosis and neurocysticercosis as pathogens affecting the nervous system.

Authors:  Siddhartha Mahanty; Hector H Garcia
Journal:  Prog Neurobiol       Date:  2009-12-24       Impact factor: 11.685

View more
  29 in total

Review 1.  Under seize: neurocysticercosis in an immigrant woman and review of a growing neglected disease.

Authors:  Meredith Bock; Hector H Garcia; Peter Chin-Hong; Sanjiv M Baxi
Journal:  BMJ Case Rep       Date:  2015-12-18

Review 2.  Clinical symptoms, diagnosis, and treatment of neurocysticercosis.

Authors:  Hector H Garcia; Theodore E Nash; Oscar H Del Brutto
Journal:  Lancet Neurol       Date:  2014-11-10       Impact factor: 44.182

Review 3.  Current status and future perspectives on the medical treatment of neurocysticercosis.

Authors:  Isidro Gonzales; Hector H Garcia
Journal:  Pathog Glob Health       Date:  2012-09       Impact factor: 2.894

Review 4.  Conservative management of neurocysticercosis in a patient with hematopoietic stem cell transplantation: a case report and review.

Authors:  S Purvey; K Lu; S K Mukkamalla; P Anandi; B Dumitriu; S Kranick; D A Hammoud; E O'Connell; A L Oh; J Barrett; S Mahanty; M Battiwalla
Journal:  Transpl Infect Dis       Date:  2015-06-01       Impact factor: 2.228

5.  Survey of Obstetrician-Gynecologists in the United States About Taeniasis and Cysticercosis.

Authors:  Rebecca L Hall; Britta Anderson; Jay Schulkin; Paul T Cantey; Susan P Montgomery; Jeffrey L Jones
Journal:  Am J Trop Med Hyg       Date:  2016-11-14       Impact factor: 2.345

6.  Neurocysticercosis in immigrant populations.

Authors:  Hector H Garcia
Journal:  J Travel Med       Date:  2012 Mar-Apr       Impact factor: 8.490

Review 7.  Taenia solium Cysticercosis and Its Impact in Neurological Disease.

Authors:  Hector H Garcia; Armando E Gonzalez; Robert H Gilman
Journal:  Clin Microbiol Rev       Date:  2020-05-27       Impact factor: 26.132

8.  Enhanced steroid dosing reduces seizures during antiparasitic treatment for cysticercosis and early after.

Authors:  Hector H Garcia; Isidro Gonzales; Andres G Lescano; Javier A Bustos; E Javier Pretell; Herbert Saavedra; Theodore E Nash
Journal:  Epilepsia       Date:  2014-08-04       Impact factor: 5.864

Review 9.  Neurocysticercosis in sub-Saharan Africa: a review of prevalence, clinical characteristics, diagnosis, and management.

Authors:  Andrea Sylvia Winkler
Journal:  Pathog Glob Health       Date:  2012-09       Impact factor: 2.894

Review 10.  Edema surrounding calcified intracranial cysticerci: clinical manifestations, natural history, and treatment.

Authors:  Theodore Nash
Journal:  Pathog Glob Health       Date:  2012-09       Impact factor: 2.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.